ABSTRACT Introduction: Karyotype analysis has been the standard method for prenatal cytogenetic diagnosis since the 1970's. Although highly reliable, the major limitation remains the requirement for cell culture, resulting in a delay of as much as 14 days to obtain test results. Fluorescence in situ hybridisation (FISH) and quantitative fluorescent PCR (QF-PCR) rapidly detect common chromosomal abnormalities but do not provide a genomewide screen for unexpected imbalances. Microarray based comparative genomic hybridisation (array-CGH) has the potential to combine the speed of DNA analysis with a broad capacity to scan for genomic abnormality. Methods: We have developed a genomic microarray of approximately 600 large-insert clones designed to detect aneuploidy, known microdeletion syndromes and large unbalanced chromosomal rearrangements. This array was tested alongside an array with an approximate resolution of 1Mb in a blind study of 30 cultured prenatal and postnatal samples with microscopically confirmed unbalanced rearrangements. Results: At 1Mb resolution, 22/30 rearrangements were identified, whereas 29/30 aberrations were detected using the custom-designed array, due to the inclusion of specifically chosen clones to give increased resolution at genomic loci clinically implicated in known microdeletion syndromes. Both arrays failed to identify a triploid karyotype. Thirty normal control samples produced no false positive results. Analysis of 30 uncultured prenatal samples showed that array-CGH is capable of detecting aneuploidy in DNA isolated from as little as 1ml of uncultured amniotic fluid; 29/30 samples were correctly diagnosed, the exception being another case of triploidy. Discussion: These studies demonstrate the potential for array-CGH to replace conventional cytogenetics in the great majority of prenatal diagnosis cases.
INTRODUCTION
Mainly as a result of screening programmes for the prenatal detection of chromosome abnormalities, approximately 40,000 amniocentesis and chorion villus samples are processed annually in the UK 1 . The vast majority of these samples (around 90-95%) yield a normal karyotype by full microscopic analysis. A small proportion of cases reveal a chromosome abnormality, about 80% of which are autosomal trisomies for chromosomes 13, 18 and 21. The remaining abnormal karyotypes involve sex chromosome copy number changes and structural chromosomal rearrangements, such as deletions, duplications, inversions and balanced and unbalanced translocations.
Microscopic analysis has been the gold standard for prenatal diagnosis since the development of chromosome banding techniques in the late 1960's 2 . Although highly reliable, this procedure has a number of limitations (reviewed in 3 ). Due to the need for cell culture, the average reporting time for results in the UK can be up to 14 days. In addition, microscopic karyotyping is labour-intensive and thus costly, requires skilled interpretation and is not easily amenable to automation. The resolution is limited, with deletions and duplications <10Mb not reliably being detected. Although high resolution methods have been shown to detect abnormalities of 3-5Mb, these procedures are not suitable for routine screening applications (reviewed in 4 ). When a structural chromosome abnormality is suspected, techniques such as fluorescence in situ hybridisation (FISH) or quantitative fluorescent PCR (QF-PCR) can be deployed, but a significant proportion of structural changes are not anticipated at the time of sample collection.
In attempts to overcome some of these limitations, alternative methods for aneuploidy detection based on FISH and QF-PCR have been applied to prenatal diagnosis. QF-PCR utilises primer pairs designed to amplify sequences at several polymorphic loci in a single reaction, and is a rapid, efficient and inexpensive method that is readily amenable to automation [5] [6] [7] . FISH screening for common aneuploidies has also been applied to prenatal testing 8 . The major limitation of QF-PCR and FISH compared to microscopic karyotype analysis is that they may not detect unbalanced chromosomal rearrangements such as microdeletions, which although uncommon, account for approximately 1-2% of abnormalities detected by microscopic analysis of prenatal samples, and can have serious clinical consequences 9 . Both of these techniques have been validated and applied to clinical samples, generally in addition to, rather than replacing, microscopic analysis.
Comparative genomic hybridisation (CGH) was developed as a genome-wide screening strategy for detecting DNA copy number imbalances 10 . The DNA content of a test and reference genome are compared by differentially labelling the genomic DNA with distinct fluorochromes, before competitively hybridising the labelled samples onto normal metaphase chromosomes and analysing the resulting ratio of the fluorochromes. While CGH has been used mainly to analyse the DNA content of tumours as a tool in cancer research 11 , the technique has recently been shown to be valuable for the detection of copy number imbalances in foetal tissue following loss of pregnancy 12 . However, CGH still requires metaphase chromosomes as targets for hybridisation, limiting high resolution methods (HR CGH) to around 3Mb 13 .
Microarray based CGH (array-CGH) is similar in principle to conventional CGH 14, 15 , but uses arrayed DNA sequences instead of metaphase chromosomes as targets for hybridisation, thus providing a direct link between detected aberrations and the physical and genetic maps of the human genome. Array-CGH has a number of significant potential advantages over conventional prenatal testing, providing a technique that is not only sensitive and comprehensive, but may be amenable to automation, thus decreasing cost, labour and the reporting time of results.
Array-CGH has already been shown to be a useful tool in clinical genetics for detecting deletions and duplications in patients with mental retardation/learning difficulties beyond the limits detectable by microscopy 16, 17 ; and for the analysis of individuals with known chromosome abnormalities using a custom-designed microarray 18 . Array-CGH analysis of foetuses with multiple malformations identified genomic rearrangements which had not been observed by karyotype analysis in around 16% of cases 19 . In a study of products-of-conception from spontaneous miscarriages using a low-density array containing targeted clones of clinical significance, array-CGH was able to detect all abnormalities previously identified by microscopic karyotype analysis, and detected additional abnormalities in approximately 10% of cases 20 . The technique therefore holds some promise of combining the speed, sensitivity and potential for partial automation of a DNA based test, with the genome screening characteristics of microscopic karyotyping.
Although it is becoming accepted that array-CGH will have a place in clinical genetic testing, it is far from clear how this will best be applied. The coverage and resolution of array-CGH are dependent on the design and density of the array used. Although superficially appealing, an array covering the entire genome at very high resolution would have potential disadvantages in clinical use: more array probes are likely to generate a higher number of false positives and large arrays are more expensive to fabricate, quality control and interrogate. Recent investigations showing significant levels of copy number polymorphism in normal populations 21, 22 reinforces the desire to only test a limited number of clones, whose results do not give rise to needless complications in interpretation. We reason that, particularly for prenatal screening when time for further investigation is limited and ambiguous results cause severe anxiety, the ideal array would contain the minimum number of clones that will deliver the required diagnosis.
We have therefore designed and carefully validated an array of approximately 600 largeinsert clones, concentrated on areas of known clinical significance with dense representation across the common microdeletion regions, and with a lower representation of about one clone per 10Mb over the remainder of the genome to detect unexpected major chromosome imbalance. We have compared the performance of this array with that of a previously described array of 1Mb resolution 23 , by parallel, blind analysis of 30 pre/postnatal samples known to have unbalanced rearrangements. Because a major advantage of array technology would be lost if cell culture were required, we have further tested the array on DNA extracted from 30 samples of 1-2 ml uncultured amniotic fluid (many with abnormal chromosome constitution), surplus to requirements after diagnostic testing (publication in progress).
We believe these results provide proof of principle that array-CGH utilising a purpose designed array is rapid. Although better than cytogenetics in some respects and worse in others, it will have about the same overall capacity to detect clinically relevant chromosome abnormalities as conventional cytogenetics. It has the potential to replace karyotyping for prenatal cytogenetics, but we do not claim the current array is ideal, and further work is required to reach a consensus on the optimum configuration of an array for clinical use. Large trials will be needed to demonstrate sensitivity and specificity in clinical operating conditions.
METHODS

Array design and production
The prenatal array described in this study was developed using published protocols 23 . In brief, large-insert BAC and PAC clones were chosen from the published Golden Path of the human sequence, to cover each chromosome at a resolution of one clone every 10Mb. Additional clones were selected for the major common microdeletion syndrome regions, as far as possible covering identified critical regions and microdeletion breakpoints with overlapping clones. Approximate clone locations are shown in fig 1 ( clone list in supplementary data). Isolated clone DNA was first amplified by degenerate oligonucleotide-primed PCR (DOP-PCR), followed by secondary PCR with a 5′-aminemodified primer. Array clones were spotted in duplicate onto CodeLink TM activated glass slides. The 1Mb resolution arrays used in this study are as published previously 23 .
Array-CGH DNA labelling and array hybridisation DNA samples (0.225µg (chromosome 'add-in' experiments, normal controls and cultured samples) or 0.100 µ g (uncultured samples) for the prenatal array: 0.45µg for the1Mb resolution array) were labelled and the microarray hybridisation performed as described previously. 24 Image acquisition and data analysis Arrays were scanned using an Agilent scanner (Agilent Technologies, West Lothian, UK) and images quantified using SPOT software 25 . Further analysis was performed using a custom-designed Excel spreadsheet, in which data were normalised by dividing the ratio of each spotted clone by the median ratio of all autosomal clones. Spots were then excluded from further analysis where duplicate spot ratios differed from the duplicate mean by >10% or where the fluorescent intensities were below those of Drosophila control spots.
Array validation Chromosome 'add-in' experiments
To test the specificity and sensitivity of clones represented on the prenatal array, a series of experiments were performed in which flow-sorted chromosome DNA was added to self-versus-self hybridisations to simulate gain of each chromosome in turn 23 .
Chromosomes were flow-sorted as described 26 and DNA isolated from aliquots containing around 250,000 chromosomes using previously published methods 27 . Prior to labelling, DNA representing either approximately 2 or 4 additional copies of an individual chromosome was combined and labelled together with reference DNA and competitively hybridised against the same reference DNA. Following hybridisation and data analysis, the standard deviation for each array was calculated from the ratios comprising the 95 th percentile. Thresholds were placed at +/-4 standard deviations from the median of the 95 th percentile values. Using these settings, a clone would be expected to exceed the threshold once in every 24 hybridisations as a result of statistical variation. Clones exceeding the thresholds set for the individual experiment on chromosomes other than the 'add-in' chromosome were then identified and excluded from subsequent analyses. This method was used to identify potentially mismapped clones and clones hybridising to multiple genomic loci.
Normal controls DNA isolated from 30 normal, healthy blood donors was hybridised against reference DNA. As described for the series of chromosome 'add-in' experiments, the standard deviation for each array was calculated from the ratios comprising the 95 th percentile. Thresholds were placed at +/-4 standard deviations from the median of the 95 th percentile values and clones exceeding the thresholds set for the individual experiment identified.
Patient samples
Cultured samples Samples were selected from amongst those available with consent, to represent a broad spectrum of cytogenetic abnormalities including autosomal trisomy, sex chromosome abnormality, marker chromosomes and triploidy, with particular emphasis on those such as microdeletions, unbalanced structural rearrangements and mosaicism which pose difficulties in detection by either array-CGH or cytogenetic examination. DNA was isolated from prenatal cultured amniocytes, cultured chorionic villi or postnatal bloods for samples previously confirmed as carrying a chromosomal rearrangement by either microscopic karyotype analysis or FISH. The results of these investigations were blinded prior to further analysis by array-CGH. Clones exceeding experimental thresholds were identified using methods as described earlier.
Uncultured samples Prior to array-CGH all samples were analysed by QF-PCR and conventional cytogenetic analysis, the results of which were concealed from the person performing array-CGH. For array-CGH, DNA was extracted from chorionic villi (a single small fragment) or 1-2ml uncultured amniotic fluid using a Qiagen QIAamp blood DNA extraction mini kit with slight modification to the manufacturer's protocol. Briefly, cell pellets were resuspended in 200µl PBS and the final elution volume was 100µl. As previously described, clones exceeding experimental thresholds were identified. All samples retrieved from patients undergoing diagnostic procedures, were surplus to diagnostic requirements, and were consented for use in research studies.
RESULTS
Array validation
Chromosome 'add-in' experiments To comprehensively test hybridisation characteristics of the entire clone set represented on the prenatal array, chromosome 'add-in' experiments were performed by the addition of DNA isolated from flow-sorted chromosomes to a series of self-versus-self hybridisations. Individual chromosomes were flow-sorted, with the exception of chromosomes 9-12. Due to their similar size and base pair composition, these chromosomes are difficult to resolve into distinct populations and were therefore cosorted (reviewed in 28 ) . A representative genomic profile for a chromosome 13 'add-in' experiment is shown in fig 2. All clones mapping to chromosome 13 showed the expected increased ratio in response to the additional copies of the chromosome. However, 3 clones mapping to chromosomes 18 (RP11-16L7), 20 (RP13-329D4) and 22 (AC008103) also showed a significant ratio change identifying cross homology with chromosome 13 or incorrect mapping. Using this method for all chromosomes, we identified 69 incorrectly mapped or cross-hybridising clones (~10% of total clones), which either did not respond to the expected chromosome 'add-in', responded to DNA from a different chromosome or hybridised to multiple chromosomes. Clones identified using this method were excluded from all subsequent analyses and would not be included in future arrays.
Normal controls Validation experiments were performed in which DNA isolated from normal, healthy blood donors was hybridised against reference DNA and clones whose log 2 ratios (test/reference) exceeded the thresholds set for each particular experiment were identified. In 30 normal-versus-normal reference hybridisations, 2 clones exceeded set thresholds. The log 2 values for these clones were +0.37 and +0.38, which although significant, were substantially less than the theoretical ratios of +0.58 expected to indicate a single copy gain. Using the thresholds discussed earlier we would expect around 1 false positive result in every 24 hybridisations due to statistical variation. It would however be necessary to perform replicate or dye-swap hybridisations and to carry out alternative investigations such as FISH to distinguish a false-positive result from the possibility that these clones are reporting variation between normal individuals.
Patient samples
Array-CGH was performed using both a 1Mb resolution array and a custom-designed prenatal array in a blind study of 30 cultured prenatal or postnatal samples with known unbalanced karyotypes. Of the 30 aberrations, 22 were detected using the 1Mb resolution array, whereas 29 aberrations were identified using the prenatal array (table 1). 3, A) ), 5 examples of sex chromosome copy number abnormality (monosomy X, XXY and XYY) and microdeletions previously identified by FISH at 15q11 (Angelman and Prader-Willi syndromes, fig 3, B) and 5p (Cri-du-Chat syndrome) were observed by array-CGH using both arrays. However, microdeletions detected using the prenatal array at 4p (WolfHirschhorn syndrome), 7q11 (Williams syndrome, fig 3, C) , 22q11 (DiGeorge syndrome) and 17p11 (Smith-Magenis syndrome) were not observed using the 1Mb array as these regions are not covered by clones representing the 1Mb array clone-set.
Details of specific cases are given below Case 9
Microscopic karyotype analysis revealed an isodicentric chromosome 13, leading to trisomy for 13ptel-13q32 and monosomy for 13q32-13qtel. Array-CGH identified clones with ratios indicative of a single copy duplication or deletion.
Case 12
Case 12 had an unbalanced translocation between chromosomes 11 and 22, leading to trisomy for 11q23-11qtel and monosomy for the terminal region of the long arm of chromosome 22.
Case 22
Karyotype analysis showed 34/40 cells having an additional, small marker chromosome, positive for a chromosome 12 centromere repeat probe and a whole chromosome 12 FISH paint. Array-CGH using the prenatal array detected duplicated ratios for a single chromosome 12 clone, although the hybridisation ratios did not reach the values expected for a single copy gain, indicating either partial clone duplication or a mosaic karyotype. A similar result was observed with 12 chromosome 12 clones using the 1Mb resolution array.
Case 27
Case 27 showed 25/44 cells having a marker chromosome, which was positive for a whole Y chromosome FISH paint. This was identified using array analysis by the deletion of 3 or 14 clones (prenatal and 1Mb array respectively).
Case 28
Case 28 also exhibited a mosaic karyotype with 68/73 cells having an extra chromosome 9. Clones on chromosome 9 showed increased ratios by array-CGH, but less than those expected for a single copy gain.
Case7
Neither array was able to identify an abnormality in case 7, which had a triploid karyotype.
Uncultured prenatal samples Array-CGH was performed using the prenatal array in a blind study of 30 uncultured prenatal samples. Array-CGH failed to detect triploidy for case 50, but this sample was identified as being abnormal as ratios for clones representing chromosomes 5 and 21 were indicative of a single copy gain.
DISCUSSION
We have demonstrated the potential utility of array-CGH for the detection of chromosomal abnormalities in prenatal diagnosis. By comparing established methods of prenatal testing (microscopic karyotype analysis, FISH and QF-PCR) with array-CGH, using both a small, custom-designed array and a larger array containing clones covering the entire genome at an approximate resolution of 1Mb, we were able to show that the great majority of abnormalities can be detected using array-based methods.
The 1Mb array used in this study was previously shown to be successful for the detection of submicroscopic deletions in patients with mental retardation/learning difficulties 16 . In the current study, this array detected only 22/30 known aberrations, missing small microdeletions at 4p (Wolf-Hirshhorn syndrome), 7q (Williams syndrome), 17p (SmithMagenis syndrome) and 22q (DiGeorge syndrome) because of low clone density in these regions.
In contrast, the smaller, purpose designed prenatal array identified 29 of the 30 aberrations. This lower-density array is comprised of clones for genome-wide analysis at an approximate resolution of only around 10Mb (~450 clones) but with an additional set of around 200 clones, chosen to cover major trisomy and microdeletion regions at increased density. This array, designed with a lower overall complexity but containing clinically important clones, identified all but one of the known chromosomal abnormalities.
Particularly in light of emerging information about large copy-number variation in normal human populations 21, 22 , large arrays are likely to generate some difficulties in interpretation, at least until much more is learned about genomic copy number variation. Small, low resolution arrays are likely to be less prone to technical error, produce fewer false positive results, will be cheaper to standardise and fabricate and can be designed to avoid genomic regions with known polymorphic copy number variation. This and earlier studies 18 demonstrate that a targeted array can combine these advantages with a high detection rate for the chosen diagnostic categories.
It is important to address some of the limitations of array-CGH before this technique is considered for clinical diagnosis (reviewed in 29, 30 ). Array-CGH is unable to detect polyploidy and balanced chromosomal rearrangements as the process of data normalisation produces results only sensitive to relative dosage imbalance between different regions of the sample under test. Polyploidy (almost always triploidy) is virtually always lethal during foetal life and is generally suspected on ultrasound investigation. Where such suspicion arises, other diagnostic procedures such as QF-PCR must be used. While conventional karyotyping is able to detect balanced chromosomal rearrangements, the majority of truly balanced translocations produce no phenotypic abnormality 31 and their discovery can lead to difficult clinical decisions during pregnancy. Detection of copy number variation by array-CGH does not itself allow nondisjunction to be distinguished from unbalanced structural abnormality which is important for genetic counselling.
On the other hand, array-CGH using a carefully selected clone-set is likely to be more sensitive than microscopic karyotyping for detecting microdeletions in the tested regions. Microdeletion syndromes are contiguous gene syndromes characterised by the loss of specific chromosomal segments, and result in clinically distinct phenotypes, some of which are at least as severe as those observed with Down syndrome (reviewed in 32 ). Many of the chromosomal rearrangements associated with microdeletion syndromes are too small to be reliably identified by routine microscopic karyotype analysis and are therefore often only detected after birth by FISH analysis using locus specific probes [33] [34] [35] .
Precisely which chromosomal regions to include in a designed prenatal array will require continued discussion including laboratory, clinical and patient viewpoints. In the array described in this study, we included major eponymous microdeletion regions. However, we deliberately excluded regions where copy number change is associated with mild or no phenotypic abnormality. Inclusion of more pericentromeric clones would improve the likelihood of detecting supernumerary marker chromosomes.
Array-CGH using a small array is therefore likely to detect all major aneuploidies, and to be more sensitive than microscopy at detecting microdeletions within areas of suspicion. It will not detect polyploidy, balanced structural rearrangements, and some unexpected relatively small unbalanced rearrangements which happen not to fall over areas of clone coverage. Mosaicism, by its nature, is likely to present problems for either technique. In this series we noted clone ratios suggestive of less than a single copy gain in 2 of the 3 mosaics tested, with the third case of mosaicism being identified as a deletion, but further data is needed to define the real sensitivity of array-CGH for mosaicism. In practise, array-CGH (in common with QF-PCR and FISH) will be used on uncultured material, and is therefore likely to produce some differences from cytogenetics performed on cultured cells with the opportunity for differential cell lineage proliferation. We would estimate that, over all categories of abnormality, the two techniques will have rather similar sensitivity for detection of clinically important changes.
Array-CGH analysis of cell-free foetal DNA isolated from amniotic fluid samples has shown promising results, with foetal sex and whole-chromosome changes being determined 36 . However, higher levels of clone to clone variability were noted when compared to cultured amniocytes, so it is possible that smaller changes involving only a few clones might not be reliably identified using this method. In this study, DNA isolated from both cultured and uncultured amniocytes was used for hybridisation. We found that array-CGH can work well on DNA from uncultured amniocytes. Since we have had to work with material surplus to diagnostic requirement, we performed array-CGH on DNA derived from as little as 1ml of uncultured amniotic fluid; in practice, performance would doubtless be better with more material. The ability to perform array-CGH on uncultured prenatal cells has not previously been established.
Array-CGH has the potential to combine the speed and capacity for automation of a DNA based technique, with the genome-wide scanning capability of conventional cytogenetics. We believe these results provide proof of principle that array-CGH utilising a purpose designed array is rapid, and may have about the same overall capacity to detect clinically relevant chromosome abnormalities as conventional cytogenetics. It has the potential to replace karyotyping for prenatal cytogenetics, but considerable further work is required to reach a consensus on the optimum configuration of an array for clinical use; and large trials are needed to demonstrate sensitivity and specificity in clinical operating conditions before the clinical implementation of array-CGH can be considered.
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Figure 3
Array-CGH data for samples 5(A), 1(B) and 2(C) (table 1), on both the prenatal (a) and 1Mb (b) arrays. The X axis represents the chromosome (A) or the distance in Mb from the p telomere (B and C). The Y axis represents the hybridisation ratio given as a log 2 scale. Significant gains are shown in green whereas significant losses are red (A) trisomy 21, (B) deletion at 7q11.23 observed on the prenatal array but absent at 1Mb resolution and (C) deletion at 15q11.2-15q13.1 visible on both arrays The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in JMG editions and any other BMJPGL products to exploit all subsidiary rights, as set out in our licence (http://jmg.bmjjournals.com/misc/ifora/licenceform.shtml)
